US EU Trade Deal: Tariff Status in October 2026

Key takeaways
The US EU trade deal is a framework announced on August 21, 2025 that set a 15% all-inclusive US tariff ceiling for most EU goods and MFN-only treatment for generics, aircraft and unavailable natural resources.
The US applied it from September 1, 2025, with auto changes back-dated to August 1, 2025, but the reciprocal tariffs behind the 15% ceiling ended after the Supreme Court's IEEPA ruling of February 20, 2026.
As of October 2026, most EU goods face a Section 301 duty that tops the MFN rate up to a combined 10%, with exemption annexes that include certain chemicals for pharmaceutical applications.
Patented pharmaceuticals from the EU face a 15% Section 232 rate unless a lower or zero rate applies, while generic pharmaceuticals are not subject to that tariff at this time.
HTSUS 9903.02.76 and 9903.02.77 were the 2025 exemption headings for EU civil aircraft and non-patented pharmaceutical articles, so check with your broker how they matter for older entries.
The US EU trade deal set out to cap US tariffs on most European goods at 15% and to exempt generic medicines, aircraft and a list of natural resources from the extra duties. That was the position in late 2025. As of October 2026 the picture is different: the emergency tariffs that the 15% ceiling was built on have ended, a new Section 301 duty applies to most EU goods at a combined 10%, and patented medicines sit under a separate Section 232 tariff at 15%.
This guide explains what the framework is, how the United States implemented it, what changed in 2026, how pharmaceuticals are treated and what HTSUS 9903.02.76 and 9903.02.77 mean today. Every rate here was checked against official sources in October 2026. Tariffs change quickly, so confirm the rate for your exact product and entry date with your customs broker before you price or ship. For background on how the earlier tariff rounds affected businesses, see our earlier analysis of US-EU tariff changes.
What is the US-EU trade deal?
The US-EU trade deal is a political framework, not a full free trade agreement. Its formal name is the Framework on an Agreement on Reciprocal, Fair, and Balanced Trade, and many importers call it the US-EU joint framework agreement because it was published as a joint statement. The White House joint statement of August 21, 2025 set out the main commitments on each side.
On the US side, the statement committed to apply the higher of the US most-favored-nation (MFN) tariff or a 15% all-inclusive rate to most EU goods. From September 1, 2025, only the MFN rate would apply to unavailable natural resources such as cork, all aircraft and aircraft parts, and generic pharmaceuticals with their ingredients and chemical precursors. The US also said that Section 232 tariffs on pharmaceuticals, semiconductors and lumber from the EU would not exceed 15%, and that auto tariffs would fall to a combined 15% once the EU introduced its own tariff legislation.
On the EU side, the statement said the EU intends to eliminate tariffs on all US industrial goods and improve access for some US agricultural and seafood products. It also described expected EU purchases of US energy valued at $750 billion and $600 billion of additional European investment in the United States through 2028. Those figures are stated as intentions and expectations rather than binding obligations.
The EU trade deal with US partners therefore works in two directions. US importers care mostly about the US tariff side, while US exporters to Europe care about the EU's tariff cuts.
When did the US-EU framework take effect?
The US side took effect in stages in 2025. Executive Order 14346 of September 5, 2025 authorized implementation, and a joint notice from the Commerce Department and USTR, published in the Federal Register on September 25, 2025, amended the HTSUS. The changes applied to goods entered on or after September 1, 2025 for the reciprocal tariff exemptions and aircraft, and on or after August 1, 2025 for EU automobiles and auto parts under Section 232.
The EU side came later. The European Commission announced on May 20, 2026 that the European Parliament and the Council had reached political agreement on two regulations that eliminate tariffs on all US industrial goods and give preferential access to certain US agricultural and seafood products. The Commission said the market access would last until the end of 2029, with the possibility of extension, and that the regulations include a safeguard clause and the power to suspend concessions. Trade publications report that the regulations applied from July 1, 2026. If an EU tariff cut affects your exports, confirm the application date and your product's annex in the Official Journal of the EU with your EU importer or broker.
What changed in 2026
The US tariffs that the 15% ceiling relied on did not last. A CBP rule published on June 24, 2026 explains that the Supreme Court held in Learning Resources, Inc. v. Trump that the International Emergency Economic Powers Act (IEEPA) does not authorize the President to impose tariffs. Executive Order 14389 of February 20, 2026 then terminated the additional duties imposed under IEEPA. On the same day, Proclamation 11012 imposed a temporary 10% surcharge under Section 122 of the Trade Act of 1974 for 150 days.
The current framework for most EU goods came from USTR in July 2026. Its notice of action published on July 28, 2026 closed 60 Section 301 investigations into forced labor import prohibitions, including one on the European Union, and imposed duties on goods entered on or after July 24, 2026.
What tariff rate applies to EU goods under the framework?
As of October 2026, most products of the European Union pay a Section 301 duty set so that the MFN rate plus the Section 301 duty equals 10%. If the MFN rate is already 10% or higher, the Section 301 duty is zero. The USTR notice states this formula for products of the EU and Taiwan, and the EU lines appear in HTSUS headings 9903.05.38 and 9903.05.39, with 9903.05.39 covering goods whose MFN rate is below 10%.
That means the EU tariff 15% ceiling announced in 2025 no longer describes most EU goods. It still matters in two places: Section 232 tariffs on EU patented pharmaceuticals and the Section 232 auto adjustments made in September 2025. The table below summarizes the main layers for healthcare and life science importers.
Product type from the EU | Main US tariff layer as of October 2026 | HTSUS Chapter 99 reference | What to confirm |
|---|---|---|---|
Most goods, including many medical devices, instruments and consumables | Section 301 duty that tops MFN up to a combined 10%, or zero if MFN is 10% or more | 9903.05.38 or 9903.05.39 | Whether your line is in an exemption annex |
Goods listed in the general Section 301 exemption annex | No Section 301 duty, MFN rate applies | 9903.05.86 | Exact 10-digit HTSUS line |
Chemicals exempt only for pharmaceutical applications | No Section 301 duty when used in pharmaceutical applications | 9903.05.89 | End-use documentation |
EU-specific exemption list | No Section 301 duty for listed lines | 9903.05.97 | Whether your line appears in the EU annex |
Patented pharmaceuticals and associated ingredients | Section 232 rate of 15% unless a lower or zero rate applies | 9903.04.60 to 9903.04.66 series | Patent status, manufacturer and zero-rate eligibility |
Generic pharmaceuticals | Not subject to the Section 232 pharmaceutical tariff at this time | Depends on line | Whether Section 301 or an exemption applies |
Two shipments from the same German or Irish supplier can therefore carry very different duties. A diagnostic analyzer with a free MFN rate may pay 10%, a product listed in an exemption annex may pay only MFN and a patented biologic may pay 15% under Section 232. Classification is the first step, and our guide to HS codes for healthcare and life sciences explains how to approach it.
How are pharmaceuticals treated under the US-EU agreement?
Under the US-EU agreement as implemented today, patented pharmaceuticals from the EU face a 15% Section 232 tariff unless a lower or zero rate applies, and generic pharmaceuticals are not subject to the Section 232 pharmaceutical tariff at this time. The 2025 framework promised that Section 232 tariffs on EU pharmaceuticals would not exceed 15%, and the 2026 proclamation delivered that cap.
The Section 232 proclamation on pharmaceuticals of April 2, 2026 sets a default 100% duty on patented pharmaceuticals and associated active ingredients listed in its annex. It then sets 15% for products of the European Union, Japan, South Korea, and Switzerland and Liechtenstein. Several details shape the real cost of Section 232 tariffs pharmaceutical goods carry:
The duties apply from July 31, 2026 for companies listed in Annex III of the proclamation and from September 29, 2026 for other companies.
Generic pharmaceuticals are not subject to the Section 232 tariff at this time, and biosimilars are also excluded.
A zero rate can apply to orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates and certain medical countermeasures, subject to conditions in the proclamation.
Companies with approved onshoring plans pay a reduced rate, and eligible companies with most-favored-nation pricing agreements receive a zero rate until January 20, 2029.
The July 2026 Section 301 notice lists patented pharmaceutical articles in headings 9903.04.60 to 9903.04.66 among the Section 232 goods that do not also pay the Section 301 duty.
For life science importers, the key questions are now whether a product is patented, who made it, whether it fits a zero-rate category and which HTSUS line applies. Clinical trial material, biologics and cell therapies each need that review before the first entry. Our article on how US pharma tariffs affect costs, supply and trade covers the wider effect on the sector.
What are HTSUS 9903.02.76 and 9903.02.77?
HTSUS 9903.02.76 and 9903.02.77 are the Chapter 99 headings created in September 2025 to exempt certain EU goods from the IEEPA reciprocal tariffs. Heading 9903.02.76 covers EU civil aircraft, meaning all aircraft other than military aircraft and unmanned aircraft, with their engines, parts, components and ground flight simulators. Heading 9903.02.77 covers EU products that are non-patented articles for use in pharmaceutical applications and that are classified in the HTSUS lines listed in the notice.
The same September 2025 notice created 9903.02.74 for unavailable natural resources such as cork and 9903.02.75 for a separate list of EU products. In each case the effect was that the reciprocal duties under headings 9903.02.19 and 9903.02.20 did not apply.
Because the IEEPA duties were terminated in February 2026, these headings no longer reduce a duty on new entries in the way they did in 2025. They still matter for entries made between September 2025 and February 2026, for example when reviewing whether duties were paid correctly or whether IEEPA duties can be recovered. Ask your broker how CBP is handling those older entries and whether any reporting requirement for these headings remains in your entry software.
What healthcare importers should check now
Whether you call it the EU US trade deal or the US trade deal with EU partners, the practical work is the same: check each product against the current layers rather than relying on the headline. A short routine helps:
Confirm the 10-digit HTSUS classification and the country of origin for each product.
Check whether the product falls under a Section 232 action, such as patented pharmaceuticals, autos, metals or semiconductors.
If not, check the Section 301 exemption annexes before applying 9903.05.38 or 9903.05.39.
For pharmaceuticals, document patent status, manufacturer and any zero-rate basis in the entry file.
Watch for new Federal Register notices and CBP messages that change rates, annexes or dates.
Your licensed customs broker should confirm the final entry lines, and CBP is the authority on scope questions. Mercury's customs brokerage team can review classifications and Chapter 99 headings before goods leave Europe, and an active US customs bond is required for formal entries. For a comparison with another partner on a different tier, see our guide to the US-Japan tariff framework, where most goods are capped at a combined 12.5%.
Planning EU shipments with fewer surprises
Tariff questions often land on time-sensitive goods. A shipment of clinical trial supplies or temperature-sensitive biologics held at the border because patent status is undocumented still needs its cold chain maintained. Planning the customs documentation and the transport together reduces the risk that a paperwork question becomes a temperature excursion. Mercury handles customs brokerage and temperature-controlled shipping for medical device and life science companies importing from the EU, and can check how the current US EU trade deal rules apply to your product list before the next shipment moves.



